目前和新兴的药物治疗方法用于治疗多变性心肌病症
Akiva Rosenzveig1, Neil Garg2, Shiavax J Rao3
1New York Medical College, Valhalla, NY, USA.
Expert opinion on pharmacotherapy
|June 5, 2023
概括
超性心肌病 (HCM) 的治疗方法正在扩大. 心脏肌肉酶抑制剂 (CMIs) 对阻塞性和非阻塞性心脏肌肉酶抑制剂具有前景,为患者提供了新的希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 增高性心肌病变 (HCM) 是一种常见的遗传性心脏病,治疗选择有限.
- 阻塞性HCM由于左心室外流通道阻塞而带来挑战.
- 目前的疗法提供最小的益处,隔膜缩小疗法并不普遍适用.
研究的目的:
- 审查超性心肌病治疗选择的不断变化的景观.
- 突出新兴药理学药物的出现和未来的治疗策略.
主要方法:
- 审查当前的指导方针和新兴的研究在HCM治疗.
- 分析心脏肌化酶抑制剂 (CMIs) 和其他药物类别的作用.
- 探索潜在的基因疗法应用.
主要成果:
- 心脏肌肉酶抑制剂 (CMIs) 在阻塞性和非阻塞性HCM中都表现出积极的结果.
- 目前正在进行的研究目标是通道,心肌能量和重新定位的药物.
- 基因疗法为HCM提供了潜在的未来治疗途径.
结论:
- 对HCM的治疗选择正在迅速扩大.
- 心脏肌肉酶抑制剂 (CMIs) 正在成为HCM治疗的基石.
- 超性心肌病治疗的未来是乐观的.
相关概念视频
Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470


